Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
Non-GLP-1 obesity drugs are emerging, with this landscape expected to surge 50-fold over the next five years, generating $15.5bn in 2031.
Drug Development
UCB to purchase Neurona and NRTX-1001 for $1.15bn
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Nucleai and Sirona Dx to provide new proteomics solution for pharma companies
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Adcendo secures $75m in Series C funding for ADC development
Lilly to acquire CrossBridge Bio for up to $300m
